

# Diagnostic Imaging Pathways - Bone Pain

## Population Covered By The Guidance

This pathway provides guidance for imaging patients with bone pain. There are links to other pathways for imaging patients with suspected bony metastases, myeloma, soft tissue masses, low back pain or joint pain in various joints.

**Date reviewed: August 2013**

**Date of next review: 2017/2018**






**Published: October 2013**

## Quick User Guide

Move the mouse cursor over the **PINK** text boxes inside the flow chart to bring up a pop up box with salient points.


Clicking on the **PINK** text box will bring up the full text.

The relative radiation level (RRL) of each imaging investigation is displayed in the pop up box.

SYMBOL	RRL	EFFECTIVE DOSE RANGE
	None	0
	Minimal	< 1 millisieverts
	Low	1-5 mSv
	Medium	5-10 mSv
	High	>10 mSv

## Pathway Diagram

Date reviewed: August 2013  
 Please note that this pathway is subject to review and revision



## Image Gallery

Pending clarification of consent

## Teaching Points

- Plain radiography of the symptomatic area is the initial investigation of choice for bone pain or suspected primary bone lesion. Most primary bone tumours are benign, but primary malignant bone tumours are an important cause of cancer morbidity and mortality in young people
- Advanced imaging modalities provide complimentary information to each other
- MRI is generally the advanced imaging modality of choice to further characterise radiograph findings or to further investigate persisting localised symptoms after a normal radiograph

- CT is useful to further define bony anatomy and in suspected osteoid osteoma and bone biopsy guidance
- Nuclear medicine studies are useful in suspected multifocal osseous pathology (e.g. bony metastases, osteomyelitis), metabolic bone disease and inflammatory arthropathy.
- If lesion diagnosis is uncertain and management will be altered, bone biopsy can be considered after review by a musculoskeletal tumour surgeon, taking into account lesion accessibility and patient comorbidities

## Red Flags: Clinical Assessment in Bone Pain

- 'Red flags' that prompt imaging include signs and symptoms suggestive of malignancy, infection, fracture or certain rheumatological, metabolic or neurological conditions
- A patient with symptoms suggestive of bone cancer or sarcoma should have specialist referral. A history of increasing, unexplained or persistent bone pain, particularly pain at rest (especially if not in the joint), an unexplained limp, or a mass/swelling arising from any bone should be investigated urgently [1](#)
- In older patients metastases, myeloma or lymphoma, as well as sarcoma, should be considered [1](#)

## Plain Radiography

- Initial imaging modality of choice for patients with localised bone pain to screen for tumours and tumour-like conditions [2](#)
- If radiographic features are definitively benign, further imaging may not be necessary unless further anatomic information is required, there is concern of secondary complications (such as pathological fracture) or surgery is contemplated [2](#)
- If multiple myeloma is suspected a radiographic skeletal survey is more sensitive than bone scintigraphy [3](#) and still considered the gold standard initial imaging modality to detect osteolytic lesions [4](#)
- A patient with persistent pain after conservative management should have further imaging despite normal radiographs, as substantial bone mineral content loss has to occur before changes become radiographically apparent

## Magnetic Resonance Imaging (MRI)

- MRI can further evaluate indeterminate or potentially malignant findings on radiography or bone scan, providing superior contrast resolution, anatomical detail and assessment of bone marrow and soft tissue involvement [5-10](#)
- It is the localised advanced imaging modality of choice for suspected osteomyelitis, primary or secondary bone tumour, occult stress or pathological fracture and soft tissue mass that may be associated with bone pain
- Allows definition of bone tumour size and local intraosseous and extraosseous extent, and is useful in the assessment of tissue characteristics, vascularity and necrosis [11-14](#)
- Limitations
  - Longer scanning time and respiratory movement artefact mean MRI is not as well suited to depicting the thoracic wall. [6](#) CT is better suited
  - Contraindicated in the presence of a ferromagnetic substance; e.g. pacemaker, aneurysm clip, cochlear implant, ocular foreign body, spinal cord stimulator and some stent materials

## Computed Tomography (CT)

- Alternative if MRI is contraindicated or unavailable
- Superior to MRI in revealing cortical integrity and the extent of structural destruction. [6,8](#) Useful for further evaluation of matrix mineralisation, calcification, cortical or periosteal involvement and pathological fractures [2,10,13](#)
- More accurate than MRI in detecting the characteristic nidus of osteoid osteoma, a benign tumour which usually affects the long bones, particularly the proximal femur and tibial shaft, [15,16](#) although the use of dynamic gadolinium-enhanced MRI improves nidus conspicuity compared to CT, especially at atypical sites [17,18](#)
- Useful for further evaluation of rib pathology after abnormal radiograph or bone scan [19,20](#)
- Dual energy CT may be used to noninvasively diagnose and monitor gouty tophi or calcium crystal deposits by analysis of the chemical composition of the scanned materials [21](#)
- Useful in guiding needle biopsy

## Bone Scintigraphy

- Nuclear medicine studies are useful in multifocal osseous pathology (e.g. bony metastases, osteomyelitis), metabolic bone disease and inflammatory arthropathy. [22](#) Technetium-99 (99mTc) accumulates at sites of elevated bone turnover
- Initial imaging modality of choice in detecting bone metastases, regardless of presence of symptoms
- Advantages
  - Allows total body survey [23](#)
  - Sensitive
- Limitations
- Non-specific; radiographic correlation and further anatomic characterisation with MRI or CT is often required
- Some lytic bone metastases may not show increased uptake on bone scan, [3](#) and are better detected by metabolic scans such as FDG-PET because they have a high glucose metabolism [24](#) or anatomical assessment with CT or MRI

## Positron Emission Tomography (PET)

- Can identify metabolically active skeletal metastases that may or may not have detectable structural destruction
- Its use in staging and follow up evaluation is increasing for a number of malignancies, including Ewing sarcoma family tumours [25](#)
- However, it is associated with high radiation exposure and cost [8](#)

## References

Date of literature search: June 2013

The search methodology is available on request. [Email](#)

References are graded from Level I to V according to the Oxford Centre for Evidence-Based Medicine, Levels of Evidence. [Download the document](#)

1. National Institute for Health and Care Excellence (NICE). **NICE Clinical Guideline 27: Referral guidelines for suspected cancer.** 2005 [updated 2011 April; cited 2013 June 25th]. (Evidence based guidelines). [View the guidelines](#)
2. Expert Panel on Musculoskeletal Imaging; Morrison W, Zoga A, Daffner RH, Weissman BN, Bancroft L, et al. **ACR Appropriateness Criteria: Primary bone tumours.** American College of Radiology; 2009 [cited 2013 April 1]. (Evidence based guideline). [View the guideline](#)
3. Ludwig H, Kumpan W, Sinzinger H. **Radiography and bone scintigraphy in multiple myeloma: a comparative analysis.** Br J Radiol. 1982;55(651):173-81. (Level III evidence)
4. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. **International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.** Leukemia. 2009;23(9):1545-56. (Evidence based guidelines)
5. Frank JA, Ling A, Patronas NJ, Carrasquillo JA, Horvath K, Hickey AM, et al. **Detection of malignant bone tumors: MR imaging vs scintigraphy.** AJR Am J Roentgenol. 1990;155(5):1043-8. (Level III evidence)
6. Hogeboom WR, Hoekstra HJ, Mooyaart EL, Freling NJ, Veth RP, Postma A, et al. **MRI or CT in the preoperative diagnosis of bone tumours.** Eur J Surg Oncol. 1992;18(1):67-72. (Level II evidence)
7. Bloem JL, Taminiau AH, Eulderink F, Hermans J, Pauwels EK. **Radiologic staging of primary bone sarcoma: MR imaging, scintigraphy, angiography, and CT correlated with pathologic examination.** Radiology. 1988;169(3):805-10. (Level II evidence)
8. Yu HHM, Tsai Y-Y, Hoffe S. **Overview of diagnosis and management of metastatic disease to bone.** Cancer Control. 2012;19(2):84-91. (Review article)
9. Ilaslan H, Schils J, Nageotte W, Lietman SA, Sundaram M. **Clinical presentation and imaging of bone and soft-tissue sarcomas.** Cleve Clin J Med. 2010;77 Suppl 1:S2-7. (Review article)
10. Pettersson H, Gillespy T, 3rd, Hamlin DJ, Enneking WF, Springfield DS, Andrew ER, et al. **Primary musculoskeletal tumors: examination with MR imaging compared with conventional modalities.** Radiology. 1987;164(1):237-41. (Level III evidence)
11. Collins MS, Koyama T, Swee RG, Inwards CY. **Clear cell chondrosarcoma: radiographic, computed tomographic, and magnetic resonance findings in 34 patients with pathologic correlation.** Skeletal Radiol. 2003;32(12):687-94. (Level II evidence)
12. Murphey MD, Jelinek JS, Temple HT, Flemming DJ, Gannon FH. **Imaging of periosteal osteosarcoma: radiologic-pathologic comparison.** Radiology. 2004;233(1):129-38. (Level II/III evidence)
13. Littrell LA, Wenger DE, Wold LE, Bertoni F, Unni KK, White LM, et al. **Radiographic, CT, and MR imaging features of dedifferentiated chondrosarcomas: a retrospective review of 174 de novo cases.** Radiographics. 2004;24(5):1397-409. (Level II/III evidence)
14. Murphey MD, wan Jaovisidha S, Temple HT, Gannon FH, Jelinek JS, Malawer MM. **Telangiectatic osteosarcoma: radiologic-pathologic comparison.** Radiology. 2003;229(2):545-53. (Level III evidence)
15. Assoun J, Richardi G, Railhac JJ, Baunin C, Fajadet P, Giron J, et al. **Osteoid osteoma: MR imaging versus CT.** Radiology. 1994;191(1):217-23. (Level III evidence)
16. Davies M, Cassar-Pullicino VN, Davies AM, McCall IW, Tyrrell PN. **The diagnostic accuracy of MR imaging in osteoid osteoma.** Skeletal Radiol. 2002;31(10):559-69. (Level III evidence)
17. Zampa V, Bargellini I, Ortori S, Faggioni L, Cioni R, Bartolozzi C. **Osteoid osteoma in atypical locations: the added value of dynamic gadolinium-enhanced MR imaging.** Eur J Radiol. 2009;71(3):527-35. (Level III evidence)
18. Liu PT, Chivers FS, Roberts CC, Schultz CJ, Beauchamp CP. **Imaging of osteoid osteoma**



**with dynamic gadolinium-enhanced MR imaging.** Radiology. 2003;227(3):691-700. (Level III evidence)

19. Niitsu M, Takeda T. **Solitary hot spots in the ribs on bone scan: value of thin-section reformatted computed tomography to exclude radiography-negative fractures.** J Comput Assist Tomogr. 2003;27(4):469-74. (Level II/III evidence)
20. Levine BD, Motamedi K, Chow K, Gold RH, Seeger LL. **CT of rib lesions.** AJR Am J Roentgenol. 2009;193(1):5-13. (Review article)
21. Dalbeth N, Choi HK. **Dual-energy computed tomography for gout diagnosis and management.** Curr Rheumatol Rep. 2013;15(1):301. (Review article)
22. The Royal College of Radiologists. **iRefer 7.0.1: Making the best use of clinical radiology.** 2012 [updated 2012 Jan; cited 2013 May 5]; 7. (Evidence based guideline). [View the guideline](#)
23. Schaffer DL, Pendergrass HP. **Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate.** Radiology. 1976;121(2):431-4. (Level III evidence)
24. Du Y, Cullum I, Illidge T, Ell P. **Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.** J Clin Oncol. 2007;25(23):3440-7. (Level II evidence)
25. Treglia G, Salsano M, Stefanelli A, Mattoli MV, Giordano A, Bonomo L. **Diagnostic accuracy of (1)(8)F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis.** Skeletal Radiol. 2012;41(3):249-56. (Level I/II evidence)

## Information for Consumers

Information from this website	Information from the Royal Australian and New Zealand College of Radiologists' website
<p><a href="#">Consent to Procedure or Treatment</a></p> <p><a href="#">Radiation Risks of X-rays and Scans</a></p> <p style="padding-left: 40px;"><a href="#">Bone Scan</a></p> <p style="padding-left: 40px;"><a href="#">Computed Tomography (CT)</a></p> <p><a href="#">Magnetic Resonance Imaging (MRI)</a></p> <p style="padding-left: 40px;"><a href="#">Plain Radiography (X-ray)</a></p>	<p><a href="#">Computed Tomography (CT)</a></p> <p><a href="#">Contrast Medium (Gadolinium versus Iodine)</a></p> <p style="padding-left: 40px;"><a href="#">Gadolinium Contrast Medium</a></p> <p style="padding-left: 40px;"><a href="#">Iodine-Containing Contrast Medium</a></p> <p><a href="#">Magnetic Resonance Imaging (MRI)</a></p> <p style="padding-left: 40px;"><a href="#">Plain Radiography/X-rays</a></p> <p><a href="#">Radiation Risk of Medical Imaging During Pregnancy</a></p> <p style="padding-left: 40px;"><a href="#">Radiation Risk of Medical Imaging for Adults and Children</a></p>



## Copyright

© Copyright 2015, Department of Health Western Australia. All Rights Reserved. This web site and its content has been prepared by The Department of Health, Western Australia. The information contained on this web site is protected by copyright.

## Legal Notice

Please remember that this leaflet is intended as general information only. It is not definitive and The Department of Health, Western Australia can not accept any legal liability arising from its use. The information is kept as up to date and accurate as possible, but please be warned that it is always subject to change

## File Formats

Some documents for download on this website are in a Portable Document Format (PDF). To read these files you might need to download Adobe Acrobat Reader.



## [Legal Matters](#)